Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Gro...(carbamazepine) extended-release capsules...)

DAYTRANA(TM) (methylphenidate transdermal system)

ELAPRASE(R) (idursulfase)

FOSRENOL(R) (lanthanum carbonate)

INTUNIV(TM) (guanfacine) extended release

LIALDA(TM) (mesalamine)

MEZAVANT(R) (mesalazine)

REMINYL(R) (galantamine hydrobromide) (UK and Republic of Ireland)

REMINYL XL(TM) (galantamine hydrobromide) (UK and Republic of Ireland)

REPLAGAL(R) (agalsidase alfa)

VYVANSE(TM) (lisdexamfetamine dimesylate)

XAGRID(R) (anagrelide hydrochloride)

The following are trademarks of third parties referred to in this press release:

3TC (lamivudine) (trademarks of GlaxoSmithKline (GSK))

AMIGAL (migalastat hydrochloride) (trademark of Amicus)

COMBIVIR (lamivudine) (trademark of GSK)

DYNEPO (epoetin delta) (trademark of Sanofi Aventis)

EPIVIR (lamivudine) (trademark of GSK)

EPZICOM (lamivudine) (trademark of GSK)

JUVISTA (trademark of Renovo)

PENTASA (mesalamine) (trademark of Ferring)

PLICERA (isofagomine tartrate) (trademark of Amicus)

RAZADYNE (galantamine) (trademark of Johnson & Johnson)

RAZADYNE ER (galantamine) (trademark of Johnson & Johnson)

REMINYL (galantamine) (trademark of Johnson & Johnson, excluding UK and

Republic of Ireland)

REMINYL XL (galantamine) (trademark of Johnson & Johnson, excluding UK

and Republic of Ireland)

SOLARAZE (diclofenac sodium (3%w/w)) (trademark of Almirall)

VANIQA (eflornithine hydrochloride) (trademark of Almirall)

ZEFFIX (lamivudine) (trademark of GSK)

Overview of US GAAP Financial Results

1. Introduction

Summary of 2007 Revenues from continuing operations for the year to December 31, 2007 increased by 36% to $2,436.3 million (2006: $1,796.5 million).

Operating loss for the year to December 31, 2007 was $1,379.1 million (2006: income of $283.2 million). The loss in 2007 primarily ar
'/>"/>